PDF(Pubmed)
Abstract：
BACKGROUND: Cardiovascular disease (CVD) remains the foremost cause of mortality globally. Taurine, an amino acid, holds promise for cardiovascular health through mechanisms such as calcium regulation, blood pressure reduction, and antioxidant and anti-inflammatory effects. Despite these potential benefits, previous studies have yielded inconsistent results. This meta-analysis of randomized controlled trials (RCTs) aims to evaluate the existing evidence on the quantitative effects of taurine on hemodynamic parameters and cardiac function grading, which are indicative of overall cardiovascular health and performance.
METHODS: We conducted an electronic search across multiple databases, including Embase, PubMed, Web of Science, Cochrane CENTRAL, and ClinicalTrials.gov, from their inception to January 2, 2024. Our analysis focused on key cardiovascular outcomes, such as heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular ejection fraction (LVEF), and New York Heart Association (NYHA) Functional Classification. Meta-regression was applied to explore dose-dependent relationships based on the total taurine dose administered during the treatment period. A subgroup analysis, stratified according to the baseline disease status of patients, was also conducted.
RESULTS: The analysis included a pooled sample of 808 participants from 20 randomized controlled trials. Taurine demonstrated a significant reduction in HR (weighted mean difference [WMD] = -3.579 bpm, 95% confidence interval [CI] = -6.044 to -1.114, p = 0.004), SBP (WMD = -3.999 mm Hg, 95% CI = -7.293 to -0.706, p = 0.017), DBP (WMD: -1.435 mm Hg, 95% CI: -2.484 to -0.386, p = 0.007), NYHA (WMD: -0.403, 95% CI: -0.522 to -0.283, p < 0.001), and a significant increase in LVEF (WMD: 4.981%, 95% CI: 1.556 to 8.407, p = 0.004). Meta-regression indicated a dose-dependent reduction in HR (coefficient = -0.0150 per g, p = 0.333), SBP (coefficient = -0.0239 per g, p = 0.113), DBP (coefficient = -0.0089 per g, p = 0.110), and NYHA (coefficient = -0.0016 per g, p = 0.111), and a positive correlation with LVEF (coefficient = 0.0285 per g, p = 0.308). No significant adverse effects were observed compared to controls. In subgroup analysis, taurine significantly improved HR in heart failure patients and healthy individuals. Taurine significantly reduced SBP in healthy individuals, heart failure patients, and those with other diseases, while significantly lowered DBP in hypertensive patients It notably increased LVEF in heart failure patients and improved NYHA functional class in both heart failure patients and those with other diseases.
CONCLUSIONS: Taurine showed noteworthy effects in preventing hypertension and enhancing cardiac function. Individuals prone to CVDs may find it advantageous to include taurine in their daily regimen.
METHODS: We conducted an electronic search across multiple databases, including Embase, PubMed, Web of Science, Cochrane CENTRAL, and ClinicalTrials.gov, from their inception to January 2, 2024. Our analysis focused on key cardiovascular outcomes, such as heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular ejection fraction (LVEF), and New York Heart Association (NYHA) Functional Classification. Meta-regression was applied to explore dose-dependent relationships based on the total taurine dose administered during the treatment period. A subgroup analysis, stratified according to the baseline disease status of patients, was also conducted.
RESULTS: The analysis included a pooled sample of 808 participants from 20 randomized controlled trials. Taurine demonstrated a significant reduction in HR (weighted mean difference [WMD] = -3.579 bpm, 95% confidence interval [CI] = -6.044 to -1.114, p = 0.004), SBP (WMD = -3.999 mm Hg, 95% CI = -7.293 to -0.706, p = 0.017), DBP (WMD: -1.435 mm Hg, 95% CI: -2.484 to -0.386, p = 0.007), NYHA (WMD: -0.403, 95% CI: -0.522 to -0.283, p < 0.001), and a significant increase in LVEF (WMD: 4.981%, 95% CI: 1.556 to 8.407, p = 0.004). Meta-regression indicated a dose-dependent reduction in HR (coefficient = -0.0150 per g, p = 0.333), SBP (coefficient = -0.0239 per g, p = 0.113), DBP (coefficient = -0.0089 per g, p = 0.110), and NYHA (coefficient = -0.0016 per g, p = 0.111), and a positive correlation with LVEF (coefficient = 0.0285 per g, p = 0.308). No significant adverse effects were observed compared to controls. In subgroup analysis, taurine significantly improved HR in heart failure patients and healthy individuals. Taurine significantly reduced SBP in healthy individuals, heart failure patients, and those with other diseases, while significantly lowered DBP in hypertensive patients It notably increased LVEF in heart failure patients and improved NYHA functional class in both heart failure patients and those with other diseases.
CONCLUSIONS: Taurine showed noteworthy effects in preventing hypertension and enhancing cardiac function. Individuals prone to CVDs may find it advantageous to include taurine in their daily regimen.
摘要：
背景：心血管疾病（CVD）仍然是全球死亡的首要原因。牛磺酸,一种氨基酸,通过钙调节等机制对心血管健康充满希望，血压降低,和抗氧化和抗炎作用。尽管有这些潜在的好处，以往的研究结果不一致.这项对随机对照试验（RCTs）的荟萃分析旨在评估牛磺酸对血流动力学参数和心功能分级的定量影响的现有证据。这表明总体心血管健康和表现。
方法：我们在多个数据库中进行了电子搜索，包括Embase,PubMed,WebofScience,科克伦中部,和ClinicalTrials.gov,从成立到2024年1月2日。我们的分析集中在关键的心血管结局，例如心率（HR），收缩压（SBP），舒张压（DBP），左心室射血分数(LVEF),和纽约心脏协会（NYHA）功能分类。基于治疗期间给予的总牛磺酸剂量，应用Meta回归来探索剂量依赖性关系。亚组分析，根据患者的基线疾病状态进行分层，也进行了。
结果：分析包括来自20项随机对照试验的808名参与者的合并样本。牛磺酸显示HR显着降低（加权平均差[WMD]=-3.579bpm，95%置信区间[CI]=-6.044至-1.114，p=0.004)，SBP(WMD=-3.999mmHg,95%CI=-7.293至-0.706，p=0.017），DBP(WMD:-1.435mmHg,95%CI：-2.484至-0.386，p=0.007），NYHA（WMD：-0.403，95%CI：-0.522至-0.283，p<0.001），LVEF显著增加(大规模杀伤性武器：4.981%，95%CI：1.556至8.407，p=0.004）。Meta回归表明HR呈剂量依赖性降低（系数=-0.0150/g，p=0.333)，SBP(系数=-0.0239/g,p=0.113)，DBP(系数=-0.0089/g,p=0.110)，和NYHA(系数=-0.0016/g，p=0.111)，与LVEF呈正相关(系数=0.0285/g，p=0.308）。与对照相比,没有观察到显著的不良反应。在亚组分析中，牛磺酸显着改善心力衰竭患者和健康个体的HR。牛磺酸显着降低健康个体的SBP，心力衰竭患者,和那些患有其他疾病的人，而高血压患者的DBP显着降低，心力衰竭患者的LVEF显着增加，心力衰竭患者和其他疾病患者的NYHA功能分级均得到改善。
结论：牛磺酸在预防高血压和增强心脏功能方面具有显著作用。容易患CVD的个体可能会发现在其日常治疗方案中包括牛磺酸是有利的。
方法：我们在多个数据库中进行了电子搜索，包括Embase,PubMed,WebofScience,科克伦中部,和ClinicalTrials.gov,从成立到2024年1月2日。我们的分析集中在关键的心血管结局，例如心率（HR），收缩压（SBP），舒张压（DBP），左心室射血分数(LVEF),和纽约心脏协会（NYHA）功能分类。基于治疗期间给予的总牛磺酸剂量，应用Meta回归来探索剂量依赖性关系。亚组分析，根据患者的基线疾病状态进行分层，也进行了。
结果：分析包括来自20项随机对照试验的808名参与者的合并样本。牛磺酸显示HR显着降低（加权平均差[WMD]=-3.579bpm，95%置信区间[CI]=-6.044至-1.114，p=0.004)，SBP(WMD=-3.999mmHg,95%CI=-7.293至-0.706，p=0.017），DBP(WMD:-1.435mmHg,95%CI：-2.484至-0.386，p=0.007），NYHA（WMD：-0.403，95%CI：-0.522至-0.283，p<0.001），LVEF显著增加(大规模杀伤性武器：4.981%，95%CI：1.556至8.407，p=0.004）。Meta回归表明HR呈剂量依赖性降低（系数=-0.0150/g，p=0.333)，SBP(系数=-0.0239/g,p=0.113)，DBP(系数=-0.0089/g,p=0.110)，和NYHA(系数=-0.0016/g，p=0.111)，与LVEF呈正相关(系数=0.0285/g，p=0.308）。与对照相比,没有观察到显著的不良反应。在亚组分析中，牛磺酸显着改善心力衰竭患者和健康个体的HR。牛磺酸显着降低健康个体的SBP，心力衰竭患者,和那些患有其他疾病的人，而高血压患者的DBP显着降低，心力衰竭患者的LVEF显着增加，心力衰竭患者和其他疾病患者的NYHA功能分级均得到改善。
结论：牛磺酸在预防高血压和增强心脏功能方面具有显著作用。容易患CVD的个体可能会发现在其日常治疗方案中包括牛磺酸是有利的。
